AstraZeneca signs USD 1.46 billion AI deal: October 30 tests AstraZeneca stock

Published on 10/23/2026 at 10:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 30, 2026 with USD 16.02 billion revenue expected. AstraZeneca stock costs EUR 152.38 on October 23, 2026.

Pipeline and reporting dates

Insitro will receive USD 40.00 million upfront under the October 15, 2026 collaboration.
RBC forecasts USD 16.30 billion in third-quarter revenue and USD 2.61 core earnings per share.
AstraZeneca stock trades at EUR 152.38 at 10:14 a.m. CEST at Lang & Schwarz on October 23, 2026.

Makroaufnahme bunter Tabletten und Kapseln mit glänzenden Wassertropfen — AstraZeneca plc (ISIN GB0009895292) entwickelt und produziert verschreibungspflichtige Tabletten, Kapseln und weitere Arzneiformen, Illustration mit AI erstellt.

AstraZeneca (ISIN GB0009895292) had agreed on October 15, 2026 to a collaboration with insitro that could generate up to USD 1.46 billion in milestones. According to AstraZeneca, the agreement targets metabolic dysfunction-associated steatohepatitis and cardiomyopathies, while October 30 brings the company's next results.

AI deal expands the pipeline

The financial structure limits AstraZeneca's immediate commitment while giving it exclusive worldwide rights to selected programs. Insitro receives USD 40.00 million upfront, with milestone payments of up to USD 1.46 billion and potential royalties under the October 15 agreement, according to AstraZeneca. The commercial payoff remains dependent on research, development and regulatory progress.

What does October 30 put on the line?

The third-quarter report is the next measurable test of the pipeline strategy. Proactive Investors reported on October 15 that RBC Capital Markets kept its Outperform rating and GBp 14,500.00 target, forecasting USD 16.30 billion in third-quarter revenue and core earnings per share of USD 2.61, versus consensus of USD 16.00 billion and USD 2.59.

MarketBeat reported on October 23 that analysts expect third-quarter revenue of USD 16.02 billion and earnings per share of USD 2.59. The same report said AstraZeneca's second-quarter revenue was USD 15.38 billion, up 6.40 percent year over year, while earnings per share reached USD 2.63 versus USD 2.50 consensus.

Three dated signals shape setup

On October 6, 2026, Citigroup raised its target to GBp 18,600.00 from GBp 17,800.00, according to Pluang; on October 15, AstraZeneca announced the USD 1.46 billion insitro milestone opportunity; on October 23, the Lang & Schwarz price stood at EUR 152.38.

Two dates define the next test

AstraZeneca's investor calendar lists an ESMO management event for October 26, 2026 and third-quarter and nine-month results for October 30, 2026, according to the company's investor relations page. The results date matters because management can update full-year guidance after the first half delivered revenue growth of 6.00 percent and core earnings per share growth of 11.00 percent, according to Proactive Investors.

Stock price stays central

AstraZeneca stock was trading at EUR 152.38 at Lang & Schwarz on October 23, 2026 at 10:14 a.m. CEST. On the LSE, AZN was at GBp 12,756.00 at 9:23 a.m. BST on October 23, 2026, with a 52-week range of GBp 9,892.00 to GBp 15,732.00 and market capitalization of GBP 197.8 billion. The company is listed on the LSE, Stockholm exchange and NYSE under AZN, as stated in AstraZeneca's release. The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.